VJHemOnc is committed to improving our service to you

SOHO 2020 | Brentuximab vedotin + nivolumab in lymphoma

VJHemOnc is committed to improving our service to you

David J. Straus

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses updates from a study evaluating brentuximab vedotin, an antibody-drug conjugate, in combination with nivolumab in relapsed/refractory Hodgkin lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter